Alcon posted strong results in Q2, driven by robust growth momentum across the segments. While returning demand for eye-care (elective) surgeries drove the Surgical’s segment, the robust uptake for new products bolstered Vision Care. Driven by the solid US market trends (backed by a strong Q2), the group has upgraded its full-year outlook. While resurfacing Delta variant concerns could play spoilsport, management is confident that it is past the worst of the pandemic.
19 Aug 2021
Better than expected recovery drives full-year guidance upgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Better than expected recovery drives full-year guidance upgrade
Alcon posted strong results in Q2, driven by robust growth momentum across the segments. While returning demand for eye-care (elective) surgeries drove the Surgical’s segment, the robust uptake for new products bolstered Vision Care. Driven by the solid US market trends (backed by a strong Q2), the group has upgraded its full-year outlook. While resurfacing Delta variant concerns could play spoilsport, management is confident that it is past the worst of the pandemic.